P Murray

865 total citations
15 papers, 682 citations indexed

About

P Murray is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, P Murray has authored 15 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in P Murray's work include TGF-β signaling in diseases (3 papers), Cancer Treatment and Pharmacology (3 papers) and Estrogen and related hormone effects (3 papers). P Murray is often cited by papers focused on TGF-β signaling in diseases (3 papers), Cancer Treatment and Pharmacology (3 papers) and Estrogen and related hormone effects (3 papers). P Murray collaborates with scholars based in United Kingdom, United States and Australia. P Murray's co-authors include Alan S. Coates, Don McNeil, Michael Byrne, John Forbes, Val Gebski, David P. Kelsen, E. S. Casper, John Crown, J F Botet and Christine Parkinson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

P Murray

15 papers receiving 651 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P Murray United Kingdom 10 439 164 130 100 93 15 682
Robin Stuart‐Harris Australia 17 415 0.9× 162 1.0× 129 1.0× 71 0.7× 88 0.9× 32 725
Kristine M. Eilers United States 11 497 1.1× 362 2.2× 153 1.2× 80 0.8× 106 1.1× 13 958
G Gill Australia 8 445 1.0× 181 1.1× 135 1.0× 214 2.1× 76 0.8× 14 809
Ray Snyder Australia 10 652 1.5× 170 1.0× 251 1.9× 43 0.4× 144 1.5× 14 843
Louise Stanton United Kingdom 15 443 1.0× 138 0.8× 196 1.5× 88 0.9× 87 0.9× 36 856
Véronique Girre France 13 556 1.3× 291 1.8× 234 1.8× 149 1.5× 76 0.8× 21 1.1k
VJ Harvey New Zealand 11 450 1.0× 160 1.0× 124 1.0× 321 3.2× 175 1.9× 16 954
Phillip Blanchette Canada 16 615 1.4× 279 1.7× 156 1.2× 92 0.9× 106 1.1× 58 1.0k
John P. Enterline United States 11 208 0.5× 154 0.9× 130 1.0× 80 0.8× 78 0.8× 26 656
Akke Botma Netherlands 12 391 0.9× 199 1.2× 272 2.1× 75 0.8× 96 1.0× 20 958

Countries citing papers authored by P Murray

Since Specialization
Citations

This map shows the geographic impact of P Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Murray more than expected).

Fields of papers citing papers by P Murray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Murray. The network helps show where P Murray may publish in the future.

Co-authorship network of co-authors of P Murray

This figure shows the co-authorship network connecting the top 25 collaborators of P Murray. A scholar is included among the top collaborators of P Murray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P Murray. P Murray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Ajithkumar, Thankamma, et al.. (2006). Ifosfamide Encephalopathy. Clinical Oncology. 19(2). 108–114. 73 indexed citations
3.
Ko, Y.J., Scott R. Berry, D. Scott Ernst, et al.. (2006). Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 24(18_suppl). 2078–2078. 3 indexed citations
4.
5.
Charman, Susan C., et al.. (2004). Information given to patients about adverse effects of radiotherapy: a survey of patients' views. Clinical Oncology. 16(7). 479–484. 20 indexed citations
6.
Murray, P, et al.. (2002). A UK survey of tamoxifen prescribing and oestrogen receptor status. The Breast. 11(3). 265–266. 1 indexed citations
7.
Shamash, Jonathan, et al.. (2001). Carboplatin AUC8 in combination with etoposide and bleomycin in the treatment of intermediate and poor-risk metastatic germ cell tumours: a phase II study. Cancer Chemotherapy and Pharmacology. 47(4). 370–372. 2 indexed citations
8.
Murray, P, Jennifer J. Gomm, David Ricketts, T.J. Powles, & R. Charles Coombes. (1994). The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: an immunocytochemical study. European Journal of Cancer. 30(9). 1218–1222. 14 indexed citations
9.
Murray, P, Peter Barrett‐Lee, M T Travers, et al.. (1993). The prognostic significance of transforming growth factors in human breast cancer. British Journal of Cancer. 67(6). 1408–1412. 68 indexed citations
10.
Coates, Alan S., Val Gebski, P Murray, et al.. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group.. Journal of Clinical Oncology. 10(12). 1833–1838. 256 indexed citations
11.
Kelsen, David P., David Lovett, Jason Wong, et al.. (1992). Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer.. Journal of Clinical Oncology. 10(2). 269–274. 39 indexed citations
12.
Crown, John, E. S. Casper, J F Botet, P Murray, & David P. Kelsen. (1991). Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology. 9(9). 1682–1686. 100 indexed citations
13.
Perry, L. A., et al.. (1990). 4-hydroxyandrostenedione – further clinical and extended endocrine observations. British Journal of Cancer. 62(2). 309–313. 36 indexed citations
14.
Ganesan, TS, P. F. M. Wrigley, P Murray, et al.. (1990). Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital. British Journal of Cancer. 62(2). 314–318. 21 indexed citations
15.
Murray, P, et al.. (1990). The prognostic significance of transcripts for transforming growth factor alpha and beta1 and epidermal growth factor receptor in primary breast cancer. European Journal of Cancer and Clinical Oncology. 26(2). 159–159. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robin Stuart‐Harris Breakdown of academic impact, for papers by Kristine M. Eilers Breakdown of academic impact, for papers by G Gill Breakdown of academic impact, for papers by Ray Snyder Breakdown of academic impact, for papers by Louise Stanton Breakdown of academic impact, for papers by Véronique Girre Breakdown of academic impact, for papers by VJ Harvey Breakdown of academic impact, for papers by Phillip Blanchette Breakdown of academic impact, for papers by John P. Enterline Breakdown of academic impact, for papers by Akke Botma
Rankless by CCL
2026